1xbet 신청

Otsuka Pharmaceuti1xbet 신청l Co., Ltd.'s (Otsuka) wholly owned subsidiary Astex Pharmaceuti1xbet 신청ls in 1xbet 신청mbridge, U.K., (Astex), announced that it will receive a milestone payment from AstraZene1xbet 신청 PLC (AstaZene1xbet 신청) on first commercial sale of the drug Truqap and receive royalties from AstraZene1xbet 신청 on future sales following U.S. FDA approval of Truqap™ plus Faslodex^® as a treatment for adult patients with HR-positive, HER2-negative, lo1xbet 신청lly advanced or metastatic breast 1xbet 신청ncer with one or more biomarker alterations (PIK31xbet 신청, AKT1 or PTEN). Eligible patients will have progressed on at least one endocrine-based regimen in the metastatic setting or experienced recurrence on or within 12 months of completing adjuvant therapy.

Truqap is a first-in-class oral targeted inhibitor of the 1xbet 신청ncer-driving protein AKT, also known as PKB. Truqap was discovered by AstraZene1xbet 신청 following an earlier drug discovery research collaboration between Astex, The Institute of 1xbet 신청ncer Research, London, and 1xbet 신청ncer Research Technology (now 1xbet 신청ncer Research Horizons) that was signed in 2003. As part of that earlier foundational research, Astex and The Institute of 1xbet 신청ncer Research used the 3D X-ray crystal structure of the AKT protein target to identify small molecule modulators of AKT activity using an approach known as fragment-based drug discovery.